[
    [
        {
            "time": "",
            "original_text": "贝达药业PD-1制剂获批临床；复星医药新药获批临试；绿叶制药新药上市申请获受理",
            "features": {
                "keywords": [
                    "贝达药业",
                    "PD-1制剂",
                    "复星医药",
                    "新药",
                    "绿叶制药",
                    "上市申请",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药",
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业PD-1制剂获批临床",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]